Cargando…
Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)
More than 40 compounds have been formally licensed for clinical use as antiviral drugs, and half of these are used for the treatment of HIV infections. The others have been approved for the therapy of herpesvirus (HSV, VZV, CMV), hepadnavirus (HBV), hepacivirus (HCV) and myxovirus (influenza, RSV) i...
Autor principal: | De Clercq, Erik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146830/ https://www.ncbi.nlm.nih.gov/pubmed/32288473 http://dx.doi.org/10.1016/S1075-8593(06)05002-7 |
Ejemplares similares
-
Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses
por: De Clercq, Erik
Publicado: (2007) -
Antivirals and antiviral strategies
por: Clercq, Erik De
Publicado: (2004) -
Three decades of antiviral drugs
por: Clercq, Erik De
Publicado: (2007) -
Editorial overview: Antiviral strategies: Antiviral drug development for single-stranded RNA viruses
por: Brinton, Margo A, et al.
Publicado: (2019) -
Recent highlights in the development of new antiviral drugs
por: De Clercq, Erik
Publicado: (2005)